Breast and ovarian cancer ▲ Public Health Genomics Knowledge Base (v1.2)

Public Health Genomics Knowledge Base (v1.2)






Last Updated: Nov 03, 2016

• Do Ovarian Cancer Patients with a Family History of Cancer (Suspected BRCA1 or BRCA2 Mutation) Suffer Greater Chemotherapy Toxicity?
  Egloff Heidi et al. Cancer investigation 2016 Oct 1-5
• Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples.
  Badoer Cindy et al. Oncotarget 2016 Oct
• The CHEK2 del5395 is a founder mutation without direct effects for cancer risk in the latvian population.
  Plonis J, et al. Balkan journal of medical genetics : BJMG 2015 12 (2) 33-36
• Whole-exome sequencing of Finnish hereditary breast cancer families.
  Määttä Kirsi, et al. European journal of human genetics : EJHG 2016 10
• http://www.mdedge.com/jcso/article/110048/gynecologic-cancer/hereditary-breast-and-ovarian-cancer-risk-assessment-minority
  Disease: Breast Cancer|Ovarian Cancer; Type: Data|Program; State: Georgia
• Implementing a screening tool for identifying patients at risk for hereditary breast and ovarian cancer: a statewide initiative.
  Disease: Ovarian Cancer|Breast Cancer; Type: Data|Program; State: Georgia
• A Relational Approach to Genetic Counseling for Hereditary Breast and Ovarian Cancer.
  Forbes Shepherd Rowan et al. Journal of genetic counseling 2016 Oct
• BRACAVENIR - impact of a psychoeducational intervention on expectations and coping in young women (aged 18-30 years) exposed to a high familial breast/ovarian cancer risk: study protocol for a randomized controlled trial.
  Kwiatkowski Fabrice et al. Trials 2016 Oct 17(1) 509
• Prevention and Screening in Hereditary Breast and Ovarian Cancer.
  Zeichner Simon B et al. Oncology (Williston Park, N.Y.) 2016 Oct 30(10)
• The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?
  Eliade Marie et al. Oncotarget 2016 Oct
• Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.
  Zaaijer Leendert H, et al. British journal of cancer 2016 10
• Prevalence of Hispanic BRCA1 and BRCA2 mutations among hereditary breast and ovarian cancer patients from Brazil reveals differences among Latin American populations.
  Alemar Bárbara, et al. Cancer genetics 2016 9 (9) 417-422
• A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
  Isakoff Steven J, et al. Future oncology (London, England) 2016 10
• Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry.
  Fernandes Gabriela C, et al. Oncotarget 2016 10
• Moving In and Out of the What-Ifs: The Experiences of Unaffected Women Living in Families Where a Breast Cancer 1 or 2 Genetic Mutation Was Not Found.
  Schroeder Dawn et al. Cancer nursing 2016 Oct

• CDC Information (8)
• CDC-Authored Pub (2)

• Human (28)
• Pathogen (0)

• Human (714)
• Pathogen (0)

• Human (165)
• Pathogen (0)

• Guidelines (8)
• Tier Table (3)
• Synthesis (8)

• Huamn (85)
• Pathogen (0)

Relevant Resources

• Cancer Genomics and Epidemiology Navigator (CGEN)
• Genetics and Genomics Competencies Center (G2C2)
• NIH Genetic Testing Registry
• NIH MedGen Database
• Online Mendelian Inheritance in Man (OMIM)
• PharmGKB